SEARCH

SEARCH BY CITATION

References

  • 1
    Bell WN, Alton HG. A brain extract as a substitute for platelet suspension in the thromboplastin generation test. Nature 1954; 174: 8801.
  • 2
    Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. Am J Clin Path 1961; 36: 2129.
  • 3
    Barrowcliffe TW, Gray E. Studies of phospholipid reagents used in coagulation. I: some general properties and their sensitivity to factor VIII. Thromb Haemost 1981; 46: 62933.
  • 4
    Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure. J Lab Clin Med 1953; 41: 63747.
  • 5
    Over J. Methodology of the one-stage assay of factor VIII (VIII:C). In: factor VIII concentrates and their clotting activity. Scand J Haematol 1984; 33(Suppl. 41): 1324.
  • 6
    Egeberg O. Assay of antihaemophilic A, B and C factors by one-stage cephalin systems. Scand J Clin Lab Invest 1961; 13: 1406.
  • 7
    Biggs R, Douglas AS, Macfarlane RG. The formation of thromboplastin in human blood. J Physiol 1953; 119: 8996.
  • 8
    Biggs R, Eveling J, Richards G. The assay of antihaemophilic globulin activity. Br J Haematol 1955; 1: 2034.
  • 9
    Barrowcliffe TW. Methodology of the two-stage assay of factor VIII. In: factor VIII concentrates and their clotting activity. Scand J Haematol 1984; 33(Suppl. 41): 2538.
  • 10
    Barrowcliffe TW. Comparisons of one-stage and two-stage assays of factor VIII:C. In: factor VIII concentrates and their clotting activity. Scand J Haematol 1984; 33(Suppl. 41): 3954.
  • 11
    Bangham DR. A History of Biological Standardization. Bristol, UK: Society of Endocrinology, 1999. (ISBN 1 898099 14 6).
  • 12
    Brozovic M, Bangham DR. Standards for heparin. Adv Exp Med Biol 1975; 52: 16379.
  • 13
    Biggs R, Bangham DR. Standardisation of the one-stage prothrombin time test for the control of anticoagulant therapy. The availability and use of thromboplastin reference preparations. Thromb Diath Haemorrh 1971; 26: 2034.
  • 14
    Bangham DR, Biggs R, Brozovic M, Denson KWE, Skegg JL. A biological standard for measurement of blood coagulation factor VIII activity. Bull World Health Organ 1971; 45: 33751.
  • 15
    Barrowcliffe TW, Kirkwood TBL. An international collaborative assay of factor VIII clotting activity. Thromb Haemost 1978; 40: 26172.
  • 16
    Kirkwood TBL, Barrowcliffe TW. Discrepancy between 1-stage and 2-stage assay for factor VIII:C. Br J Haematol 1978; 40: 3338.
  • 17
    Barrowcliffe TW, Tydeman MS, Kirkwood TBL, Thomas DP. Standardisation of factor VIII. III: establishment of a stable reference plasma for factor VIII-related activities. Thromb Haemost 1983; 50: 6906.
  • 18
    Brozovic M, Bangham DR. Study of a proposed international standard for factor IX. Thromb Haemost 1976; 35: 22236.
  • 19
    Barrowcliffe TW. Standardisation of factors II, VII, IX, and X in plasma and concentrates. Thromb Haemost 1987; 59: 334.
  • 20
    Barrowcliffe TW, Watton J, Tubbs JE et al. Potency of high purity factor VIII concentrates (letter). Lancet 1990; ii: 124.
  • 21
    Dawson NJ, Kemball-Cook G, Barrowcliffe TW. Assay discrepancies with highly purified factor VIII concentrates. Haemostasis 1989; 19: 1317.
  • 22
    Barrowcliffe TW. Standardization and assay. In “clotting factor concentrates in clinical practice”. Semin Thromb Hemost 1993; 19: 739.
  • 23
    Barrowcliffe TW. Recommendations for the assay of high-purity factor VIII concentrates. Thromb Haemost 1993; 70: 8767.
  • 24
    Assay of human coagulation factor VIII (2.7.4). In: European Pharmacopoeia, 5th edn. Strasbourg, France: Council of Europe, 2005: 1945.
  • 25
    Raut S, Heath A, Barrowcliffe TW. Establishment of the 6th International Standard for FVIII Concentrate. Thromb Haemost 2001; 85: 10718.
  • 26
    Raut S, Bevan S, Hubbard AR, Sands D, Barrowcliffe TW. A collaborative study to establish the 7th International Standard for Factor VIII Concentrate. J Thromb Haemost 2005; 3: 11926.
  • 27
    Kirschbaum N, Wood L, Lachenbruch P et al. Calibration of the Ph. Eur. BRP Batch 3/Mega 2 (US/FDA) standard for human coagulation factor VIII concentrate for use in the potency assay. Pharmeuropa Spec Issue Biol 2002; 1: 3164.
  • 28
    Hubbard AR, Sands D, Sandberg E, Seitz R, Barrowcliffe TW. A multi-centre collaborative study on the potency estimation of ReFacto. Thromb Haemost 2003; 90: 108893.
  • 29
    Hubbard AR, Weller LJ, Bevan SA. Activation profiles of FVIII in concentrates reflect one-stage/chromogenic potency discrepancies. Br J Haematol 2002; 117: 95760.
  • 30
    Lee CA, Owens D, Bray G et al. Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay. Thromb Haemost 1999; 82: 16447.
  • 31
    Schaub RG. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochem Pharmacol 2011; 82: 918.
  • 32
    Farrugia A. Potency assessment of the new generation of coagulation factor concentrates – time for a new paradigm? Thromb Haemost 2003; 90: 96870.
  • 33
    Mei B, Pan C, Jiang H et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 2709.
  • 34
    Hubbard AR, Dodt J, Lee T et al. ; The Factor VIII & Factor IX Subcommittee of the Scientific Standardisation Committee of the International Society on Thrombosis Haemostasis. Recommendations on the potency labelling of factor VIII and factor IX concentrates. J Thromb Haemost 2013. (in press).